Alkermes (NASDAQ:ALKS) Stock Purchased Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Alkermes plc (NASDAQ:ALKS). In a filing disclosed on September 04th, the Representative disclosed that they had bought between $15,001 and $50,000 in Alkermes stock on July 30th.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Mesabi Trust (NYSE:MSB) on 7/31/2026.
• Purchased $1,001 – $15,000 in shares of Praxis Precision Medicines (NASDAQ:PRAX) on 7/30/2026.
• Sold $15,001 – $50,000 in shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 7/30/2026.
• Sold $100,001 – $250,000 in shares of Alibaba Group (NYSE:BABA) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Adobe (NASDAQ:ADBE) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of SailPoint (NASDAQ:SAIL) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of Glacier Bancorp (NYSE:GBCI) on 7/21/2026.
• Sold $1,001 – $15,000 in shares of FedEx (NYSE:FDX) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of Marvell Technology (NASDAQ:MRVL) on 7/17/2026.

Alkermes Trading Up 0.5%

ALKS stock traded up $0.24 during midday trading on Tuesday, reaching $46.34. 271,906 shares of the company traded hands, compared to its average volume of 2,111,635. Alkermes plc has a 52-week low of $26.40 and a 52-week high of $55.67. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.85 and a current ratio of 2.30. The business has a 50 day moving average of $50.43 and a 200-day moving average of $41.04. The firm has a market capitalization of $7.77 billion, a price-to-earnings ratio of 121.50 and a beta of 0.31.

Wall Street Analysts Forecast Growth

ALKS has been the topic of several recent research reports. Mizuho increased their price target on Alkermes from $53.00 to $65.00 and gave the company an “outperform” rating in a report on Thursday, July 2nd. TD Cowen boosted their price objective on shares of Alkermes from $42.00 to $50.00 and gave the company a “buy” rating in a research report on Monday, June 22nd. Bank of America reissued an “underperform” rating on shares of Alkermes in a research note on Monday, June 29th. Piper Sandler restated an “overweight” rating and issued a $65.00 target price (up from $43.00) on shares of Alkermes in a report on Tuesday, July 28th. Finally, Needham & Company LLC lifted their price target on shares of Alkermes from $61.00 to $62.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Alkermes has a consensus rating of “Moderate Buy” and a consensus target price of $54.56.

Insider Activity at Alkermes

In other news, EVP David Gaffin sold 2,034 shares of Alkermes stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $48.01, for a total value of $97,652.34. Following the transaction, the executive vice president directly owned 223,422 shares in the company, valued at approximately $10,726,490.22. This trade represents a 0.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher I. Wright sold 2,000 shares of Alkermes stock in a transaction on Friday, June 12th. The stock was sold at an average price of $45.10, for a total transaction of $90,200.00. Following the completion of the transaction, the director directly owned 25,680 shares in the company, valued at $1,158,168. This represents a 7.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 87,150 shares of company stock valued at $4,332,413 over the last quarter. 4.59% of the stock is owned by insiders.

Institutional Trading of Alkermes

Hedge funds and other institutional investors have recently bought and sold shares of the business. Cullen Frost Bankers Inc. purchased a new stake in shares of Alkermes in the 4th quarter worth $28,000. Johnson Financial Group Inc. purchased a new position in Alkermes during the 3rd quarter valued at about $31,000. UMB Bank n.a. raised its holdings in shares of Alkermes by 57.6% in the 4th quarter. UMB Bank n.a. now owns 1,220 shares of the company’s stock valued at $34,000 after purchasing an additional 446 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in shares of Alkermes by 1,041.4% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,324 shares of the company’s stock worth $37,000 after purchasing an additional 1,208 shares during the period. Finally, Ameritas Advisory Services LLC bought a new position in shares of Alkermes during the second quarter valued at approximately $39,000. Hedge funds and other institutional investors own 95.21% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.